Andrew Bell, PhD
Chemistry Consultant and Co-founder
As a one of the world’s leading medicinal chemists, Andy is a co-inventor of Sildenafil and a contributor to the development of Voriconazole; together these medicines have generated sales in excess of $40 billion.
In addition to his role as a chemistry consultant at Myricx, Andy is Chief Research Officer at Exscientia.
He had a 30 year career in research at Pfizer, followed by seven years as a Research Fellow at Imperial College London, where he led the medicinal chemistry effort on a project to discover novel inhibitors of
N-myristoyltransferase for the treatment of parasitic infections.
Andy was awarded the Technical Achievement Award in Organic Chemistry by the American Chemical Society in recognition for his contributions to medicinal chemistry.
Andy obtained a PhD in Medicinal and Pharmaceutical Chemistry from Imperial College London and a BA from the University of York.
